



ProPharmaceuticalsGroup

Pro Pharmaceuticals Group Pty LTD

ABN: 20 605 457 430

[www.propg.com.au](http://www.propg.com.au)

Dear Healthcare Professional,

### **Shortage of AUSTRAPEN ampicillin 1g (as sodium) powder for injection vial (AUST R: 29354)**

Pro Pharmaceuticals Group recognises the importance of supplying essential medicines in Australia and would like to advise you the change in supply status of AUSTRAPEN ampicillin 1g (as sodium) powder for injection vial (AUST R: 29354) in Australia.

The Australian registered medicine AUSTRAPEN ampicillin 1g (as sodium) powder for injection vial sponsored by Alphapharm is currently in shortage due to manufacturing issues.

Pro Pharmaceuticals Group has arranged for the supply of an alternative product, **Ampicillin for injection, USP 1g/vial (Eugia, USA)**. This product is NOT registered in Australia and supply is authorised under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the *Therapeutic Goods Act 1989* until **31<sup>st</sup> January 2024** for the following indication(s):

*Treatment of infections due to susceptible strains of Gram-positive and Gram-negative organisms. Bacteriological studies to determine the organism and its sensitivity should be undertaken.*

**Ampicillin for injection, USP 1g/vial (Eugia, USA)** is registered and marketed in USA therefore all labelling is in English.

**Ampicillin for injection, USP 1g/vial (Eugia, USA)** contains the same active ingredient and strength as the Australian registered product. Healthcare professionals should refer to the attached US product information and labels for reconstitution instructions.

Healthcare professionals should refer the Australian approved Product Information for recommended dosing for various indications. Australian Product Information for **AUSTRAPEN ampicillin 1g (as sodium) powder for injection vial (AUST R: 29354)** is available here: [www.ebs.tga.gov.au](http://www.ebs.tga.gov.au)

Reporting suspected adverse events is important for the continued monitoring of the safety of all medicines. Any adverse events which are experienced with **Ampicillin for injection, USP 1g/vial (Eugia, USA)** must be reported by healthcare professionals, pharmacists, and patients to the TGA at <https://www.tga.gov.au/reporting-problems> or to Pro Pharmaceuticals Group on 1300077674 or email [regulatory@propg.com.au](mailto:regulatory@propg.com.au)

Any product complaints with **Ampicillin for injection, USP 1g/vial (Eugia, USA)** should be reported to Pro Pharmaceuticals Group on 1300 077674 or email [regulatory@propg.com.au](mailto:regulatory@propg.com.au)

For any orders please contact Pro Pharmaceuticals Group on 1300077674 or email [orders@propg.com.au](mailto:orders@propg.com.au)

Please forward this information to relevant staff members in your organisation.

For further information, please contact Pro Pharmaceuticals Group on 1300077674 or email [info@propg.com.au](mailto:info@propg.com.au)

Sincerely,

Sandip Manku – Director Pro Pharmaceuticals Group